- Home
- ASTH vs FTRE Comparison
ASTH vs FTRE Comparison
Compare ASTH & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTH
- FTRE
- Stock Information
- Founded
- ASTH 1994
- FTRE 1996
- Country
- ASTH United States
- FTRE United States
- Employees
- ASTH N/A
- FTRE N/A
- Industry
- ASTH Professional Services
- FTRE Medical Specialities
- Sector
- ASTH Consumer Discretionary
- FTRE Health Care
- Exchange
- ASTH Nasdaq
- FTRE Nasdaq
- Market Cap
- ASTH 1.7B
- FTRE 1.4B
- IPO Year
- ASTH N/A
- FTRE N/A
- Fundamental
- Price
- ASTH $35.68
- FTRE $14.88
- Analyst Decision
- ASTH Strong Buy
- FTRE Hold
- Analyst Count
- ASTH 6
- FTRE 11
- Target Price
- ASTH $65.60
- FTRE $23.30
- AVG Volume (30 Days)
- ASTH 255.3K
- FTRE 1.2M
- Earning Date
- ASTH 02-27-2025
- FTRE 03-03-2025
- Dividend Yield
- ASTH N/A
- FTRE N/A
- EPS Growth
- ASTH 34.92
- FTRE N/A
- EPS
- ASTH 1.30
- FTRE N/A
- Revenue
- ASTH $1,722,367,000.00
- FTRE $2,975,600,000.00
- Revenue This Year
- ASTH $46.11
- FTRE N/A
- Revenue Next Year
- ASTH $34.25
- FTRE $1.02
- P/E Ratio
- ASTH $27.82
- FTRE N/A
- Revenue Growth
- ASTH 29.71
- FTRE 2.80
- 52 Week Low
- ASTH $29.08
- FTRE $14.27
- 52 Week High
- ASTH $63.20
- FTRE $41.02
- Technical
- Relative Strength Index (RSI)
- ASTH 43.50
- FTRE 34.60
- Support Level
- ASTH $38.31
- FTRE $14.88
- Resistance Level
- ASTH $39.97
- FTRE $15.83
- Average True Range (ATR)
- ASTH 1.49
- FTRE 0.69
- MACD
- ASTH -0.05
- FTRE 0.08
- Stochastic Oscillator
- ASTH 11.18
- FTRE 25.85
About ASTH Astrana Health Inc. Common Stock
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. Its operating segment is the healthcare delivery segment.
About FTRE Fortrea Holdings Inc.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.